

# SIMRIS GROUP CONFIRMS A TERM EXTENSION TO FLEXIBLE FUNDING FACILITY

**Simris Group AB and The Brand Laboratories FZ have agreed to extend the term of the existing flexible funding facility. The Maturity date of 31st December 2023 has been extended to 31 March 2025. Funding utilised under this facility are €777,832.**

Simris Group AB (publ) ("Simris" or the "Company") requested a maturity term extension of the flexible financing facility that The Brand Laboratories FZ (TBL"), a company associated with Simris' Chairman, Steven Schapera, provided to the Company on 25 August 2022, and which was subsequently increased on 21 April 2023. TBL has agreed to that request. As such, Simris and TBL have entered into an amended agreement to extend the term of the flexible funding facility provided by TBL. The amended agreement stipulates that the term of the flexible funding facility shall be extended to 31 March 2025. As before, interest will be charged at a rate of 1.0% per month. TBL has made no charge to Simris for this extension.

## Contact Details:

Dr Alexis Roberts-McIntosh  
CEO Simris Group AB  
Email: [ir@simris.com](mailto:ir@simris.com)  
Mobile: +44 (0) 7940 585298  
[www.simrisgroup.com](http://www.simrisgroup.com)

## About Simris Group AB (PUBL):

Simris Group is a biologics company identifying and commercialising high value, natural, biologically active compounds found in microalgae and cyanobacteria to extract for applications in biopharmaceuticals, dietary supplements and cosmetics.

Simris Group's shares are traded on the Nasdaq First North Growth Market with the short name SIMRIS and ISIN code SE0008091664.

Certified Adviser is Amudova AB, telephone: 08-546 017 58, email: [info@amudova.se](mailto:info@amudova.se).

## Attachments

[SIMRIS GROUP CONFIRMS A TERM EXTENSION TO FLEXIBLE FUNDING FACILITY](#)